High expression of cytoplasmic phosphorylated CSE1L in malignant melanoma but not in benign nevi

Phosphorylated CSE1L for the discrimination between melanoma and benign nevi

Szu Ying Chin, Pei Ru Wu, Yi Hsien Shih, Chung Min Yeh, Woan Ruoh Lee, Shing Chuan Shen, Kun Tu Yeh, Ming Chung Jiang, Jonathan Te Peng Tseng

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Melanoma is difficult to treat when it has metastasized. Discrimination between melanoma and benign nevi in melanocytic lesions is crucial for identifying melanomas and consequently improving melanoma treatment and prognosis. The chromosome segregation 1-like (CSE1L) protein has been implicated in cancer progression and is regulated by phosphorylation by extracellular signal-regulated kinase 1/2 (ERK1/2) signaling, a critical pathway in melanoma progression. We studied phosphorylated CSE1L expression in human melanoma and benign nevi specimens. Immunohistochemistry with tissue microarray using antibody against phosphorylated CSE1L showed that melanomas exhibited considerable staining for phosphorylated CSE1L (100%, 34/34), whereas the benign nevi showed only faint staining (0%, 0/34). Melanomas mainly exhibited cytoplasmic phospho-CSE1L distribution, whereas the benign nevi mainly exhibited nuclear phospho-CSE1L distribution. Moreover, immunohistochemistry with anti-CSE1L antibody revealed that CSE1L mainly exhibited cytoplasmic/nuclear distribution and nuclear distribution was the dominant. Immunofluorescence with B16F10 melanoma cells showed cytoplasmic distribution of phospho-CSE1L and nuclear distribution of CSE1L. Our results indicated that nuclear CSE1L is mainly non-phosphorylated CSE1L and is involved in gene regulation and cytoplasmic CSE1L is mainly phosphorylated CSE1L and is involved in cytoplasmic signaling regulation in melanocytic tumorigenesis. Furthermore, immunohistochemical analysis of cytoplasmic phospho-CSE1L may aid in the diagnosis of melanoma.

Original languageEnglish
Pages (from-to)1393-1401
Number of pages9
JournalInternational Journal of Clinical and Experimental Pathology
Volume8
Issue number2
Publication statusPublished - 2015

Fingerprint

Nevi and Melanomas
Chromosome Segregation
Nevus
Chromosomes, Human, Pair 1
Melanoma
Cellular Apoptosis Susceptibility Protein
Immunohistochemistry
Staining and Labeling
Pigmented Nevus
Critical Pathways
Mitogen-Activated Protein Kinase 3
Antibodies
Mitogen-Activated Protein Kinase 1

Keywords

  • CSE1L
  • Cytoplasmic
  • Melanoma
  • Nuclear
  • Phospho-CSE1L
  • Phosphorylation

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Cite this

High expression of cytoplasmic phosphorylated CSE1L in malignant melanoma but not in benign nevi : Phosphorylated CSE1L for the discrimination between melanoma and benign nevi. / Chin, Szu Ying; Wu, Pei Ru; Shih, Yi Hsien; Yeh, Chung Min; Lee, Woan Ruoh; Shen, Shing Chuan; Yeh, Kun Tu; Jiang, Ming Chung; Tseng, Jonathan Te Peng.

In: International Journal of Clinical and Experimental Pathology, Vol. 8, No. 2, 2015, p. 1393-1401.

Research output: Contribution to journalArticle

@article{8709c27bf31941568a6620ae5ce6c2fc,
title = "High expression of cytoplasmic phosphorylated CSE1L in malignant melanoma but not in benign nevi: Phosphorylated CSE1L for the discrimination between melanoma and benign nevi",
abstract = "Melanoma is difficult to treat when it has metastasized. Discrimination between melanoma and benign nevi in melanocytic lesions is crucial for identifying melanomas and consequently improving melanoma treatment and prognosis. The chromosome segregation 1-like (CSE1L) protein has been implicated in cancer progression and is regulated by phosphorylation by extracellular signal-regulated kinase 1/2 (ERK1/2) signaling, a critical pathway in melanoma progression. We studied phosphorylated CSE1L expression in human melanoma and benign nevi specimens. Immunohistochemistry with tissue microarray using antibody against phosphorylated CSE1L showed that melanomas exhibited considerable staining for phosphorylated CSE1L (100{\%}, 34/34), whereas the benign nevi showed only faint staining (0{\%}, 0/34). Melanomas mainly exhibited cytoplasmic phospho-CSE1L distribution, whereas the benign nevi mainly exhibited nuclear phospho-CSE1L distribution. Moreover, immunohistochemistry with anti-CSE1L antibody revealed that CSE1L mainly exhibited cytoplasmic/nuclear distribution and nuclear distribution was the dominant. Immunofluorescence with B16F10 melanoma cells showed cytoplasmic distribution of phospho-CSE1L and nuclear distribution of CSE1L. Our results indicated that nuclear CSE1L is mainly non-phosphorylated CSE1L and is involved in gene regulation and cytoplasmic CSE1L is mainly phosphorylated CSE1L and is involved in cytoplasmic signaling regulation in melanocytic tumorigenesis. Furthermore, immunohistochemical analysis of cytoplasmic phospho-CSE1L may aid in the diagnosis of melanoma.",
keywords = "CSE1L, Cytoplasmic, Melanoma, Nuclear, Phospho-CSE1L, Phosphorylation",
author = "Chin, {Szu Ying} and Wu, {Pei Ru} and Shih, {Yi Hsien} and Yeh, {Chung Min} and Lee, {Woan Ruoh} and Shen, {Shing Chuan} and Yeh, {Kun Tu} and Jiang, {Ming Chung} and Tseng, {Jonathan Te Peng}",
year = "2015",
language = "English",
volume = "8",
pages = "1393--1401",
journal = "International Journal of Clinical and Experimental Pathology",
issn = "1936-2625",
publisher = "E-CENTURY PUBLISHING CORP",
number = "2",

}

TY - JOUR

T1 - High expression of cytoplasmic phosphorylated CSE1L in malignant melanoma but not in benign nevi

T2 - Phosphorylated CSE1L for the discrimination between melanoma and benign nevi

AU - Chin, Szu Ying

AU - Wu, Pei Ru

AU - Shih, Yi Hsien

AU - Yeh, Chung Min

AU - Lee, Woan Ruoh

AU - Shen, Shing Chuan

AU - Yeh, Kun Tu

AU - Jiang, Ming Chung

AU - Tseng, Jonathan Te Peng

PY - 2015

Y1 - 2015

N2 - Melanoma is difficult to treat when it has metastasized. Discrimination between melanoma and benign nevi in melanocytic lesions is crucial for identifying melanomas and consequently improving melanoma treatment and prognosis. The chromosome segregation 1-like (CSE1L) protein has been implicated in cancer progression and is regulated by phosphorylation by extracellular signal-regulated kinase 1/2 (ERK1/2) signaling, a critical pathway in melanoma progression. We studied phosphorylated CSE1L expression in human melanoma and benign nevi specimens. Immunohistochemistry with tissue microarray using antibody against phosphorylated CSE1L showed that melanomas exhibited considerable staining for phosphorylated CSE1L (100%, 34/34), whereas the benign nevi showed only faint staining (0%, 0/34). Melanomas mainly exhibited cytoplasmic phospho-CSE1L distribution, whereas the benign nevi mainly exhibited nuclear phospho-CSE1L distribution. Moreover, immunohistochemistry with anti-CSE1L antibody revealed that CSE1L mainly exhibited cytoplasmic/nuclear distribution and nuclear distribution was the dominant. Immunofluorescence with B16F10 melanoma cells showed cytoplasmic distribution of phospho-CSE1L and nuclear distribution of CSE1L. Our results indicated that nuclear CSE1L is mainly non-phosphorylated CSE1L and is involved in gene regulation and cytoplasmic CSE1L is mainly phosphorylated CSE1L and is involved in cytoplasmic signaling regulation in melanocytic tumorigenesis. Furthermore, immunohistochemical analysis of cytoplasmic phospho-CSE1L may aid in the diagnosis of melanoma.

AB - Melanoma is difficult to treat when it has metastasized. Discrimination between melanoma and benign nevi in melanocytic lesions is crucial for identifying melanomas and consequently improving melanoma treatment and prognosis. The chromosome segregation 1-like (CSE1L) protein has been implicated in cancer progression and is regulated by phosphorylation by extracellular signal-regulated kinase 1/2 (ERK1/2) signaling, a critical pathway in melanoma progression. We studied phosphorylated CSE1L expression in human melanoma and benign nevi specimens. Immunohistochemistry with tissue microarray using antibody against phosphorylated CSE1L showed that melanomas exhibited considerable staining for phosphorylated CSE1L (100%, 34/34), whereas the benign nevi showed only faint staining (0%, 0/34). Melanomas mainly exhibited cytoplasmic phospho-CSE1L distribution, whereas the benign nevi mainly exhibited nuclear phospho-CSE1L distribution. Moreover, immunohistochemistry with anti-CSE1L antibody revealed that CSE1L mainly exhibited cytoplasmic/nuclear distribution and nuclear distribution was the dominant. Immunofluorescence with B16F10 melanoma cells showed cytoplasmic distribution of phospho-CSE1L and nuclear distribution of CSE1L. Our results indicated that nuclear CSE1L is mainly non-phosphorylated CSE1L and is involved in gene regulation and cytoplasmic CSE1L is mainly phosphorylated CSE1L and is involved in cytoplasmic signaling regulation in melanocytic tumorigenesis. Furthermore, immunohistochemical analysis of cytoplasmic phospho-CSE1L may aid in the diagnosis of melanoma.

KW - CSE1L

KW - Cytoplasmic

KW - Melanoma

KW - Nuclear

KW - Phospho-CSE1L

KW - Phosphorylation

UR - http://www.scopus.com/inward/record.url?scp=84928152186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928152186&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 1393

EP - 1401

JO - International Journal of Clinical and Experimental Pathology

JF - International Journal of Clinical and Experimental Pathology

SN - 1936-2625

IS - 2

ER -